Chongqing Genrix Biopharmaceutical Co., Ltd.SSE: 688443

(688443)"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Indication of Chronic Rhinosinusitis with Nasal Polyps

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688443 · · 2 pages · Chinese

Summary by 6ix AI

Chongqing Genrix Biopharmaceutical Co., Ltd. announced the acceptance of its new drug application for Telikibart Injection aimed at treating chronic rhinosinusitis with nasal polyps.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/688443chongqing-genrix-biopharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-the-acceptance-of-the-new-drug-application-for-telikibart-injection-for-the-indication-of-chronic-rhinosinusitis-with-nasal-polyps

Release

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Indication of Chronic Rhinosinusitis with Nasal Polyps

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix

Story so far

Earlier from Chongqing Genrix Biopharmaceutical

All Chongqing Genrix Biopharmaceutical news releases